148 related articles for article (PubMed ID: 23190215)
1. Extended-release antiepileptic drugs: a comparison of pharmacokinetic parameters relative to original immediate-release formulations.
Leppik IE; Hovinga CA
Epilepsia; 2013 Jan; 54(1):28-35. PubMed ID: 23190215
[TBL] [Abstract][Full Text] [Related]
2. Extended-release formulations for the treatment of epilepsy.
Bialer M
CNS Drugs; 2007; 21(9):765-74. PubMed ID: 17696575
[TBL] [Abstract][Full Text] [Related]
3. Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine.
Miller AD; Krauss GL; Hamzeh FM
Acta Neurol Scand; 2004 Jun; 109(6):374-7. PubMed ID: 15147458
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic simulations of topiramate plasma concentrations following dosing irregularities with extended-release vs. immediate-release formulations.
Brittain ST; Wheless JW
Epilepsy Behav; 2015 Nov; 52(Pt A):31-6. PubMed ID: 26409125
[TBL] [Abstract][Full Text] [Related]
5. Bioequivalence in development of antiepileptic drugs.
Sommerville KW
Epilepsy Res; 2006 Jan; 68(1):82-5. PubMed ID: 16377144
[TBL] [Abstract][Full Text] [Related]
6. Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy.
Reed RC; Dutta S; Liu W
Epilepsy Res; 2009 Dec; 87(2-3):260-7. PubMed ID: 19892524
[TBL] [Abstract][Full Text] [Related]
7. Extended-release drug formulations for the treatment of epilepsy.
Brandt C; May TW
Expert Opin Pharmacother; 2018 Jun; 19(8):843-850. PubMed ID: 29672177
[TBL] [Abstract][Full Text] [Related]
8. Extended-release formulations: simplifying strategies in the management of antiepileptic drug therapy.
Pellock JM; Smith MC; Cloyd JC; Uthman B; Wilder BJ
Epilepsy Behav; 2004 Jun; 5(3):301-7. PubMed ID: 15145298
[TBL] [Abstract][Full Text] [Related]
9. Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician.
Dutta S; Reed RC
J Clin Pharm Ther; 2006 Aug; 31(4):321-9. PubMed ID: 16882100
[TBL] [Abstract][Full Text] [Related]
10. Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations.
Ahmad A; Garnett WR
Curr Med Res Opin; 2005 Sep; 21(9):1363-8. PubMed ID: 16197654
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
Jenner P; Könen-Bergmann M; Schepers C; Haertter S
Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
[TBL] [Abstract][Full Text] [Related]
12. Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations.
Reed RC; Dutta S; Cavanaugh JH; Locke C; Granneman GR
Epilepsy Behav; 2006 Mar; 8(2):391-6. PubMed ID: 16473558
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic interactions of valproate, phenytoin, phenobarbitone and carbamazepine with curcumin in experimental models of epilepsy in rats.
Reeta KH; Mehla J; Pahuja M; Gupta YK
Pharmacol Biochem Behav; 2011 Sep; 99(3):399-407. PubMed ID: 21641922
[TBL] [Abstract][Full Text] [Related]
14. Patterns of care, outcomes, and direct health plan costs of antiepileptic therapy: a pharmacoeconomic analysis of the available carbamazepine formulations.
Garnett WR; Gilbert TD; O'Connor P
Clin Ther; 2005 Jul; 27(7):1092-103. PubMed ID: 16154489
[TBL] [Abstract][Full Text] [Related]
15. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States.
Dutta S; Reed RC
Epilepsy Res; 2007 Mar; 73(3):275-83. PubMed ID: 17208410
[TBL] [Abstract][Full Text] [Related]
16. Extended-release formulations in epilepsy.
Verrotti A; Salladini C; Di Marco G; Pisciella F; Chiarelli F
J Child Neurol; 2007 Apr; 22(4):419-26. PubMed ID: 17621521
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability of divalproex extended-release formulation relative to the divalproex delayed-release formulation.
Dutta S; Zhang Y
Biopharm Drug Dispos; 2004 Nov; 25(8):345-52. PubMed ID: 15378557
[TBL] [Abstract][Full Text] [Related]
18. What do the suffixes--XR, ER, Chrono, Chronosphere--really mean as it pertains to modified-release antiepileptic drugs?
Reed RC; Meinhold J; Dutta S; Liu W; Qiu Y
J Clin Pharm Ther; 2010 Aug; 35(4):373-83. PubMed ID: 20831540
[TBL] [Abstract][Full Text] [Related]
19. Assessing impact of real-world dosing irregularities with lamotrigine extended-release and immediate-release formulations by pharmacokinetic simulation.
Chen C; Wright J; Gidal B; Messenheimer J
Ther Drug Monit; 2013 Apr; 35(2):188-93. PubMed ID: 23503444
[TBL] [Abstract][Full Text] [Related]
20. Epilim chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers.
Roberts D; Easter D; O'Bryan-Tear G
Biopharm Drug Dispos; 1996 Mar; 17(2):175-82. PubMed ID: 8907724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
